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 The nucleophosmin 1 gene is a
frequently mutated gene in acute
myeloid leukemia.
 NPM1 mutation status was connected
with a gene expression signature.
 HOX genes and their co-factors
significantly upregulated in NPM1
mutant tumors.
 The expression of these genes also
correlated to survival.
 HOX genes with co-factors can be
therapeutic targets in NPM1 mutated
AML patients.g r a p h i c a l a b s t r a c ta r t i c l e i n f o
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Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic progenitor cells and the most com-
mon malignant myeloid disorder in adults. Several gene mutations such as in NPM1 (nucleophosmin 1)
are involved in the pathogenesis and progression of AML. The aim of this study was to identify genes
whose expression is associated with driver mutations and survival outcome. Genotype data (somatic
mutations) and gene expression data including RNA-seq, microarray, and qPCR data were used for the
analysis. Multiple datasets were utilized as training sets (GSE6891, TCGA, and GSE1159). A new clinical
sample cohort (Semmelweis set) was established for in vitro validation. Wilcoxon analysis was used to
identify genes with expression alterations between the mutant and wild type samples. Cox regression
analysis was performed to examine the association between gene expression and survival outcome.
Data analysis was performed in the R statistical environment. Eighty-five genes were identified with sig-
nificantly altered expression when comparing NPM1 mutant and wild type patient groups in the
GSE6891 set. Additional training sets were used as a filter to condense the six most significant genesmnibus;
erican–
106 Á. Nagy et al. / Journal of Advanced Research 20 (2019) 105–116associated with NPM1 mutations. Then, the expression changes of these six genes were confirmed in the
Semmelweis set: HOXA5 (P = 3.06E12, FC = 8.3), HOXA10 (P = 2.44E09, FC = 3.3), HOXB5
(P = 1.86E13, FC = 37), MEIS1 (P = 9.82E10, FC = 4.4), PBX3 (P = 1.03E13, FC = 5.4) and ITM2A
(P = 0.004, FC = 0.4). Cox regression analysis showed that higher expression of these genes – with the
exception of ITM2A – was associated with worse overall survival. Higher expression of the HOX genes
was identified in tumors harboring NPM1 gene mutations by computationally linking genotype and gene
expression. In vitro validation of these genes supports their potential therapeutic application in AML.
 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction several molecularly targeted agents were proposed for theAcute myeloid leukemia (AML) is characterized by clonal prolif-
eration of myeloid blasts. Based on statistical data, AML represents
approximately 1.1% of all new cancer cases in the U.S. and is more
common in older adults and males. The death rate is higher among
patients over 65 years and unfortunately, the rate has failed to
decrease in recent years [1]. Chromosomal structural variations
and genetic abnormalities play an essential role in the pathogene-
sis of AML [2]. According to The Cancer Genome Atlas project, the
five most common mutated genes in AML comprise NPM1, IDH1,
IDH2, DNMT3A, and FLT3 [3]. Isocitrate dehydrogenase 1/2
(IDH1/2) mutations occur in approximately 15% of AML patients,
and the frequency increases with age [4]. Mutations in IDH1/2
are associated with DNA and histone hypermethylation, altered
gene expression and blocked differentiation of hematopoietic pro-
genitor cells [5]. The FMS-like tyrosine kinase 3 (FLT3) gene
encodes a class III receptor tyrosine kinase that regulates hemato-
poiesis, including differentiation and proliferation of stem cells [6].
FLT3 mutations are correlated with worse clinical outcome in
younger adults [7]. Activating mutations in the tyrosine kinase
domain (TKD) of FLT3 exist in 15% of patients with AML.
The nucleophosmin gene (NPM1) is one of the most frequently
mutated genes in AML [8]. The normal functionofNPM1 is to control
ribosome formation and export, stabilize the oncosuppressor
p14Arf protein in the nucleolus and regulate centrosome duplica-
tion [9]. Mutations in NPM1were found in 20–30% of AML patients.
These alterations induce abnormal cytoplasmic localization of the
protein which is a critical step in leukemogenesis [8]. NPM1 muta-
tions are restricted tomyeloid cells, and aberrant cytoplasmic dislo-
cation was not observed in lymphoid cells, including the reactive
lymph nodes or B and T cells from bone marrow biopsies or periph-
eral blood [10]. NPM1 mutations are frequently associated with
internal tandem duplication (ITD) of FLT3 and DNMT3A mutations
[11,12]. In addition, besides the FLT3-ITD and DNMT3A mutations,
NPM1 mutations also co-occur with IDH1, IDH2, and TET2 muta-
tions [13]. There are mutations that rarely occur with NPM1 muta-
tions, such as partial tandem duplication in the mixed lineage
leukemia (MLL) gene and mutations in RUNX1, CEBPA, and TP53
genes [3]. FLT3 tyrosine kinase domain (TKD) mutations are rarely
accompanied by NPM1 mutations [14]. A previous study described
favorable prognosis of NPM1 mutated AML patients with normal
karyotype [15]. Another study demonstrated that karyotype, age,
NPM1 mutation status, white blood cell count, lactate dehydroge-
nase, and CD34 expression were independent prognostic markers
for overall survival [16]. A previous study also demonstrated that
IDH1 mutations are associated with favorable survival outcome in
NPM1 mutant/FLT3-ITD-negative patients [17]. Currently,
chemotherapy in younger and fit patients is still the primary treat-
ment for AML patients. Chemotherapy generally includes a combi-
nation of an anthracycline, such as daunorubicin [18] or idarubicin
[19], and cytarabine [20] agents. Of note, NPM1 mutated AML is
highly responsive to induction chemotherapy [21], and up to 80%
of patients experience complete remission with clearance of leuke-
mic cells 16 days after starting a treatment [22]. In the last decade,treatment of AML, including tyrosine kinase inhibitors, such as sor-
afenib [23], midostaurin [24], quizartinib [25], and crenolanib [26]
which inhibit the tyrosine kinase domain of the FLT3 kinase. STAT3
inhibitors, including C188-9 [27] and OPB-31121 [28], specifically
inhibit the phosphorylation of STAT3 protein,which is highly upreg-
ulated in up to 50%of AMLpatients and is associatedwithpoor prog-
nosis. There are several additional targeted agents, such as IDH1 and
IDH2 inhibitors [29,30], nuclear export inhibitors [31] and CD33 and
CD123 antigen specific inhibitors [32].
The aim was to examine the transcriptomic fingerprint of NPM1
gene mutations to shed light on transformed molecular pathways.
First, genes showing altered expression in NPM1 mutated patients
were identified and correlated these findings to different survival
outcomes in multiple different genome-wide training sets. The
best hits were validated in an independent set of patients.
Material and methods
The analysis was based on utilizing a training and a validation
set (Fig. 1A). Data processing was performed in the R v3.2.3 statis-
tical environment (http://www.r-project.org).
Preprocessing of the training set
A suitable training AML dataset with available gene expression
and clinical data was searched in the NCBI GEO repository (http://
www.ncbi.nlm.nih.gov/geo/). The keywords ‘‘AML,” ‘‘GPL570” and
‘‘GPL96” were utilized, and we filtered for those datasets that
included raw gene expression data and clinical information for
the same patients. Array quality control was performed for all sam-
ples using the ‘‘yaqcaffy” (http://bioconductor.org/packages/
yaqcaffy/) library. The background, the raw Q, the percentage of
present calls, the presence of BioB-/C-/D- spikes, the GAPDH 3’ to
5’ ratio and the beta-actin 3’–5’ ratio were assessed and used only
those arrays that passed the preset quality criteria. The MAS5 algo-
rithm by the ‘‘affy” (http://bioconductor.org/packages/affy/) library
was used to normalize the data. An additional second scaling nor-
malization was made to set the mean expression on each array to
1000. For genes measured by various probe sets, we employed
JetSet to choose the most trustworthy probe set [33].
RNA-seq and mutation data of AML patients
Two additional datasets were used for training, a gene-chip
dataset (processed as described above) and an RNA-seq dataset.
In the RNA-seq dataset, the somatic mutation data were obtained
from The Cancer Genome Atlas (TCGA, https://cancergenome.nih.
gov/). The preprocessed and annotated MAF (Mutation Annotation
Format) data files were used generated by MuTect2, MUSE,
VarScan and SomaticSniper pipelines. The ‘‘maftools” package
(http://bioconductor.org/packages/maftools/) was applied for
aggregation and visualization of mutation data.
The htseq counts RNA-seq data generated by the Illumina
HiSeq 2000 RNA Sequencing version 2 platform was used for
Fig. 1. Training set setup. Summary of the analysis workflow (A). Proportion of driver mutations and clinical characteristics of the training sets GSE6891 (B) and TCGA (C).
Distribution of the NPM1 mutation localizations in the TCGA samples (D).
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bioconductor.org/packages/AnnotationDbi/) was applied to anno-
tate Ensembl transcript IDs with gene symbols (n = 25,228). The
‘‘DESeq” package based on the negative binomial distribution
was used to normalize the raw read counts data [34].Semmelweis set
Clinical samples diagnosed at the 1st Department of Pathology-,
and Experimental Cancer Research, Semmelweis University, Buda-
pest, Hungary were utilized in the in vitro validation. All materials
and protocols were approved by the Institutional Scientific and
Research Ethics Committee of the Semmelweis University TUKEB –
14383-2/2017/EKU. Mutation status was determined by Sanger
sequencing and quantitative PCR measurement was utilized to
examine the gene expression changes.
DNA was isolated from peripheral blood and bone marrow sam-
ples using the High Pure PCR Template Preparation Kit (Roche,
Basel, Switzerland) following the manufacturer’s protocol. DNA
concentration was measured by UV spectrophotometry (Nano-
Drop; Thermo Fisher Scientific, Waltham, Massachusetts, USA).RNA isolation
The peripheral blood and bone marrow samples were homoge-
nized for 2 h using hemolysis solution containing 0.15 M NH4Cl,
10 M NH4HCO3, and 0.1 M EDTA with a pH of 7.4 (Sigma-Aldrich,
St. Louis, MO, USA). After hemolysis, samples were centrifuged at
1800 RPM for 10 min and washed with 1x phosphate-buffered sal-
ine (PBS; Lonza, Basel, Switzerland). Total RNA was isolated from
cells using TRIzol Reagent (Invitrogen, Waltham, Massachusetts,
USA) following the manufacturer’s protocol. RNA concentration
was measured by UV spectrophotometry (NanoDrop; Thermo
Fisher Scientific, Waltham, Massachusetts, USA).Sanger sequencing
The amplification of NPM1 was performed using AmpliTaqGold
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) poly-
merase mix in a PE 2720 GeneAmp (Perkin-Elmer, Waltham,
Massachusetts, USA) PCR machine. Forward (50- TTC CAT ACA
TAC TTA AAA CCA A-30) and reverse (50- TGG TTC CTT AAC CAC
ATT TCT TT 30) primers were employed in a 25 mL final volume.
108 Á. Nagy et al. / Journal of Advanced Research 20 (2019) 105–116The reaction mix contained 2x AmpliTaqGold mix, 400 nM of each
primer and 100 ng of DNA. Amplification started with denaturation
for 10 min at 95 C, and then 95 C for 30 sec, 56 C for 60 sec and
72 C for 60 sec were repeated for 40 cycles. The PCR products were
cleaned using ExoSAP-IT PCR Product Cleanup (Affymetrix, Santa
Clara, California USA), and trailed using the Big Dye Terminator
kit v3.1 (Thermo Fisher Scientific, Waltham, Massachusetts, USA)
direct sequencing reaction following the manufacturer’s protocol.
For sequencing analysis an ABI 3500 Genetic Analyzer (Thermo
Fisher Scientific, Waltham, Massachusetts, USA) machine was used,
and the results were visualized using SeqA6 (Thermo Fisher Scien-
tific, Waltham, Massachusetts, USA) software.
Quantitative PCR measurement
For qPCR analysis, 1 mg of total RNA from each sample was tran-
scribed in a final volume of 25 mL using the High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, Mas-
sachusetts, USA). Quantitative PCR was performed using the CFX96
Real-Time PCR Machine (Bio-Rad Laboratories, Hercules, California,
USA) and SensiFAST SYBR No-ROX Kit (Bioline Reagents, London,
UK).
Primers were designed on exon-exon junctions and covering all
transcript variants of each selected gene. GAPDH and TBP genes
were used as reference genes (Table 1).
The reactions were performed in a 20 mL final volume, contain-
ing 1 mL of cDNA, diluted 2-fold, and 125 nM of each primer. After a
preliminary denaturation step of 2 min at 95 C, 40 cycles with
three steps were performed: 95 C for 15 sec, 60 C for 15 sec and
72 C for 30 sec. Each sample was measured in triplicate, and the
threshold cycle (Ct) was determined for each gene. The DCt
method was employed to evaluate gene expression changes and
we used 2(-DCt)-values of the data. WinSTAT (http://www.win-
stat.com) was used to analyze the data.
Statistical computations
First, patients were divided into a mutated and a wild-type
cohort based on the somatic mutation status of NPM1. Normal dis-
tribution of the data was checked using the Shapiro-Wilk’s W test.
Then, Wilcoxon analysis was used to identify differentially
expressed genes between the mutant and wild type cohorts. In
addition, median fold change (FC) was computed for each geneTable 1
Quantitative PCR primers for selected and references genes.
Mutation Gene NCBI nucleotide sequence
IDH1 RASGRP3 NM_015376.2 F:
R:
IDH2 NPDC1 NM_015392.3 F:
R:
NPM1 HOXA5 NM_019102.3 F:
R:
NPM1 HOXB5 NM_002147.3 F:
R:
NPM1 HOXA10 NM_018951.3 F:
R:
NPM1 ITM2A NM_001171581.1 F:
R:
NPM1 MEIS1 NM_002398.2 F:
R:
NPM1 PBX3 NM_006195.5 F:
R:
– GAPDH NM_002046.6 F:
R:
– TBP NM_003194.4 F:
R:
Annealing temperature (Temp) calculation was executed using NCBI Primer Blast (wwwto determine the direction of the expression change. Significance
was accepted for genes with less than 0.5 or higher than 2 and with
a p value below P < 0.05.
Correlation between gene expression and overall survival (OS)
was computed using Cox proportional hazards regression and by
plotting Kaplan-Meier survival plots. To calculate the prognostic
effect of a gene, each percentile of gene expression were computed
between the lower and upper quartiles and the best performing
threshold was used as the final cutoff in the Cox regression analysis
[35]. The ‘‘survival” R package (http://CRAN.R-project.org/pack-
age=survival) was applied for Cox regression analysis and ‘‘surv-
plot” R package (http://www.cbs.dtu.dk/~eklund/survplot/) to
generate Kaplan-Meier plots. Finally, q-value was computed (the
minimum false discovery rate at which the test may be called sig-
nificant) to combat multiple hypothesis testing.
Results
Analysis of the first training cohort
The training cohort was based on 536 patients from the
GSE6891 dataset [36]. The gene expression profiles of these sam-
ples were determined using Affymetrix Human Genome U133 Plus
2.0 Arrays (GPL570), and we obtained both mutation and gene
expression data for 460 of the 536 patients. The median follow-
up for overall survival (OS) was 18.7 months. Fig. 1B and Table 2
show the clinico-pathological parameters, including age, gender,
and FAB subtype. NPM1 was the most frequently mutated gene
as 30% of patients harbored a mutation. When correlating survival
length in the training cohort and NPM1 mutation status, no signif-
icant correlation was observed (P = 0.3).
Wilcoxon analysis across all genes (12,205) identified 85 genes
showing significantly altered expression in NPM1 mutant patients
compared to the NPM1 wild type cohort. Of these, 57 genes were
upregulated and 28 genes were downregulated. The full list of sig-
nificantly altered genes is displayed in Table 3. Cox regression
analysis performed for the significant genes identified a correlation
with overall survival for 47 genes at an FDR below 10% (Table 4).
Selecting genes for qPCR analysis
Two additional datasets, the TCGA and the GSE1159, were
used to filter the results to obtain the most reliable genes. ThePrimer sequence Length (bp) Temp (C)
50-CAAGCCAACCTTCTGCGAAC-30 83 60
50-TGGCTCCACAGTCTTTGCAT-30
50-GACTACGCCACTGCGAAGG-30 139 60
50-CTTTATGCCGCTCCAGGCAC-30
50-AGCTGCACATAAGTCATGACAACA-30 136 60
50-TCAATCCTCCTTCTGCGGGT-30
50-AACTCCTTCTCGGGGCGTTAT-30 138 60
50-CATCCCATTGTAATTGTAGCCGT-30
50-GAGAGCAGCAAAGCCTCGC-30 127 60
50-CCAGTGTCTGGTGCTTCGTG-30
50-TGTTGCTGGGGAACTGCTAT-30 102 60
50-GATATCTGCCACTCGCCAGTTT-30
50-CACGGGACTCACCATCCTTC-30 99 60
50-TGACTTACTGCTCGGTTGGAC-30
50-CACACCTCAGCAACCCCTAC-30 90 60
50-ACCAATTGGATACCTGTGACACT-30
50-AAATCAAGTGGGGCGATGCT-30 86 60
50-CAAATGAGCCCCAGCCTTCT-30
50-GCACAGGAGCCAAGAGTGAA-30 127 60
50-TCACAGCTCCCCACCATGT-30
.ncbi.nlm.nih.gov/tools/primer-blast/).
Table 2
Clinical characteristics of datasets.
GSE6859 TCGA GSE1159 Semmelweis set
Total number of samples 536 200 293 169
Samples with mutation & expression data 460 116 247 169
Age range (median) 15–60 (43) 18–89 (58) 15–60 (42) 0–85 (59)
Sex (F/M) 230/230 91/109 128/119 84/85
Median survival time (months) 18,7 12 17 6.92
Karyotype (good/intermediate/poor/unknown) 97/261/92/86 – 60/136/48/49 12/97/25/35
FAB subtype (M0/M1/M2/M3/M4/M5/M6) 16/95/105/24/84/104/6 – 6/55/54/17/43/62/3 –
F: female, M: male, PB: peripheral blood, BM: bone marrow.
Table 3
List of genes showing significantly altered expression when comparing NPM1 mutant
and wild type cohorts in the training set.
Gene Mutant median Wild median FC P-value
HOXB3 598.5 189 3.17 5.12E45
HOXA5 2799 100 27.99 1.87E44
HOXB2 2282 220.5 10.35 2.85E43
HOXB6 1017 83.5 12.18 4.55E43
HOXA10 2952 683.5 4.32 2.22E39
PBX3 3544.5 654 5.42 5.45E39
MEIS1 2264.5 431 5.25 1.12E38
HOXB5 840.5 321.5 2.61 1.35E38
PDGFD 665.5 227.5 2.93 2.30E33
SMC4 4415 2043.5 2.16 2.75E32
COL4A5 1342.5 100.5 13.36 1.00E31
DMXL2 4371.5 1398 3.13 3.00E31
PLA2G4A 593.5 262.5 2.26 6.11E29
CD34 257.5 1854 0.14 7.04E29
APP 49 839 0.06 3.44E28
BAALC 78.5 611 0.13 3.49E28
ITM2C 834.5 2579 0.32 2.45E27
CD200 77.5 664.5 0.12 3.38E27
H2AFY2 588.5 235.5 2.5 1.41E25
CCND2 2266.5 4802.5 0.47 2.54E24
GYPC 803.5 2440.5 0.33 5.68E23
RASGRP3 1022.5 278.5 3.67 2.54E22
JUP 702 1944 0.36 6.90E22
PRKAR2B 2554 871.5 2.93 5.88E21
TSPAN13 343.5 1157.5 0.3 1.59E20
MAN1A1 1746.5 3552.5 0.49 2.11E20
ITM2A 977.5 2989 0.33 3.81E20
H1F0 562.5 2117 0.27 1.45E18
C3AR1 1880 831.5 2.26 2.43E18
BAHCC1 1864 770 2.42 2.77E18
LPAR6 318 964 0.33 3.72E18
IFITM1 1370 2974.5 0.46 4.47E18
SEL1L3 1668.5 766.5 2.18 2.28E17
LGALS3BP 2999.5 794 3.78 3.47E17
MEST 986 3028 0.33 3.88E17
HIST2H2BE 3068 1500 2.05 5.65E16
CPVL 1442.5 553.5 2.61 1.03E15
SLC38A1 818.5 1878.5 0.44 2.49E15
EGFL7 276.5 728 0.38 3.33E15
PRKD3 331 805 0.41 6.67E15
VNN1 1144 261 4.38 9.17E15
TLR4 1193 524 2.28 3.39E14
CTSG 3670 948.5 3.87 1.66E13
JAG1 1095.5 480.5 2.28 2.63E13
TNFAIP2 2286.5 1114 2.05 5.73E13
CD36 2778 1155 2.41 2.74E12
CCNA1 1382.5 476.5 2.9 7.85E12
TARP 4965.5 2317.5 2.14 1.03E11
PPBP 1487.5 332 4.48 1.08E11
EREG 1391.5 255 5.46 1.39E11
EMP1 433 1063 0.41 2.96E11
SPINK2 2270 589.5 3.85 3.75E11
CX3CR1 2901.5 893 3.25 5.75E11
MARCKS 1786.5 635.5 2.81 9.32E11
TREM1 1000.5 447 2.24 1.19E10
BCL2A1 993 446 2.23 1.35E09
WASF1 452 911.5 0.5 2.60E09
PTX3 766 368.5 2.08 2.63E09
Table 3 (continued)
Gene Mutant median Wild median FC P-value
MAFB 1597.5 385.5 4.14 6.14E09
PF4 514.5 197 2.61 1.17E08
PROM1 320 1699.5 0.19 1.96E08
LILRB2 976 382.5 2.55 2.19E08
CYTL1 342.5 751.5 0.46 3.27E08
NPR3 479.5 1440 0.33 3.50E08
SERPINA1 4521 1940.5 2.33 8.33E08
HK3 1125 432.5 2.6 3.45E07
TMEM176B 744 263 2.83 4.79E07
SLC4A1 470 1161.5 0.4 6.02E07
HBB 6031 19,089 0.32 1.43E06
VCAN 2036 491.5 4.14 1.81E06
TMEM176A 619.5 302.5 2.05 3.33E06
BASP1 2885 1120 2.58 3.68E06
MPO 6784.5 15,838 0.43 4.05E06
CPA3 3423.5 1255.5 2.73 1.83E05
MYCN 839 390.5 2.15 2.42E05
MYOF 736.5 303.5 2.43 3.17E05
IFI30 4928 1872.5 2.63 3.24E05
CA1 764.5 1800 0.42 2.42E04
FCN1 2595.5 869 2.99 4.39E04
FGL2 2020 893 2.26 7.20E04
FPR1 1097 478.5 2.29 9.26E04
C5AR1 1231.5 609 2.02 1.48E03
ELANE 2086.5 4984 0.42 2.26E03
CD14 1211 359 3.37 5.38E03
S100A12 765 358 2.14 2.23E02
Á. Nagy et al. / Journal of Advanced Research 20 (2019) 105–116 109TCGA repository has 200 AML patients of which 152 patients had
RNA-seq gene expression data and 149 patients had somatic
mutation data (Table 2). Overall survival data were available for
175 patients, and the median follow-up time was 12 months.
There were 116 patients who had both gene expression and
mutation data. Survival analysis was not performed for this data-
set because less than half of the patients had simultaneous sur-
vival, mutation and gene expression data. The clinical
characteristics of the TCGA dataset are found in Fig. 1C and
Table 2. The GSE1159 dataset [37] includes 293 patients mea-
sured using Affymetrix Human Genome U133A Arrays (GPL96).
Follow-up with overall survival data was available for 260
patients. There were 247 patients with simultaneous gene expres-
sion and mutation data (Table 2).
In the TCGA dataset, NPM1 mutations were found in 17% of
patients, of which 75% of the mutations were frame shift inser-
tions, 20% were missense and 5% were in frame deletions
(Fig. 1D). Most of the frame shift insertions were localized at the
nucleolar localization signal region in the C-terminal DNA/RNA
binding domain of the NPM1 gene (Fig. 1D).
In the TCGA and GSE1159 datasets, 49 of the previously identi-
fied 85 genes reached statistical significance. The results of the
Wilcoxon test are listed in Table 5, and the results of the survival
analysis in Table 6.
Table 4
NPM1 mutation associated genes that expression was correlated with OS in the
training set.
Gene HR P-value q-value
MPO 2.17 2.85E07 2.42E05
HOXA5 0.55 1.15E05 4.41E04
HOXA10 0.54 1.56E05 4.41E04
CD34 0.55 2.78E05 5.71E04
TARP 0.61 3.36E05 5.71E04
SPINK2 0.63 6.59E05 9.34E04
MYOF 0.62 2.27E04 2.76E03
MEIS1 0.59 3.12E04 3.31E03
SEL1L3 0.61 3.63E04 3.43E03
PRKAR2B 0.66 5.22E04 4.44E03
H2AFY2 0.67 8.56E04 6.62E03
PRKD3 0.66 1.10E03 7.81E03
PPBP 0.68 1.35E03 8.85E03
MEST 1.53 2.10E03 1.25E02
PF4 0.68 2.21E03 1.25E02
SMC4 0.7 2.75E03 1.25E02
PLA2G4A 0.7 2.81E03 1.25E02
ELANE 1.54 2.91E03 1.25E02
BASP1 0.66 2.94E03 1.25E02
MARCKS 0.69 3.31E03 1.25E02
LILRB2 0.66 3.34E03 1.25E02
H1F0 0.68 3.36E03 1.25E02
JUP 1.5 3.38E03 1.25E02
TSPAN13 0.69 3.83E03 1.36E02
FCN1 0.71 4.58E03 1.50E02
ITM2A 1.46 4.65E03 1.50E02
PBX3 0.69 4.76E03 1.50E02
BAALC 0.69 7.04E03 2.14E02
IFI30 0.68 7.80E03 2.24E02
CPVL 0.71 8.09E03 2.24E02
VNN1 0.69 8.18E03 2.24E02
CD14 0.71 8.83E03 2.34E02
HOXB5 0.73 9.86E03 2.54E02
LGALS3BP 0.72 1.13E02 2.81E02
TNFAIP2 0.72 1.21E02 2.88E02
SLC38A1 0.74 1.22E02 2.88E02
CD200 0.73 1.38E02 3.16E02
GYPC 1.34 1.41E02 3.16E02
MYCN 0.73 1.48E02 3.23E02
COL4A5 0.75 1.54E02 3.27E02
HOXB6 0.76 1.75E02 3.59E02
FPR1 0.72 1.77E02 3.59E02
RASGRP3 0.76 1.90E02 3.75E02
EREG 0.76 2.12E02 4.10E02
MAFB 0.73 2.22E02 4.19E02
EMP1 0.73 2.61E02 4.83E02
HOXB3 0.77 2.71E02 4.90E02
CTSG 0.76 3.22E02 5.71E02
CYTL1 1.35 3.33E02 5.78E02
HOXB2 0.77 4.19E02 7.02E02
EGFL7 0.76 4.21E02 7.02E02
IFITM1 0.77 4.36E02 7.09E02
MAN1A1 1.28 4.42E02 7.09E02
Table 5
List of genes that expression was significantly altered between NPM1 mutant and
wild type cohorts in the TCGA (A) and GSE1159 (B) datasets.
Gene Mutant median Wild median FC P-value
(A)
BAALC 41.5 1010 0.04 4.75E06
HOXA5 1651.5 175.5 9.41 1.15E05
CD34 89 9587 0.01 1.18E05
GYPC 752.5 2596.5 0.29 1.26E05
HOXB3 6453 729 8.85 1.54E05
HOXB5 426.5 5 85.3 2.75E05
HOXB6 714 7.5 95.2 3.61E05
RASGRP3 2853 693.5 4.11 5.14E05
MAN1A1 1577.5 4319.5 0.37 5.91E05
PBX3 3952 895.5 4.41 6.29E05
HOXB2 750.5 199 3.77 6.48E05
CD200 37 869 0.04 7.68E05
PDGFD 377 85.5 4.41 1.10E04
COL4A5 1769 54 32.76 1.26E04
PROM1 118 3421 0.03 1.26E04
HOXA10 1164.5 318.5 3.66 1.46E04
DMXL2 9338 4220 2.21 1.51E04
MEIS1 4178 1235 3.38 1.96E04
SMC4 5938.5 3471 1.71 2.14E04
NPR3 561.5 3175 0.18 3.67E04
ITM2C 2335 3929 0.59 4.83E04
MEST 678 1710 0.4 1.27E03
BAHCC1 14,302 5990 2.39 1.49E03
TSPAN13 133.5 405 0.33 2.20E03
TMEM176B 28.5 105.5 0.27 2.90E03
TMEM176A 17 65.5 0.26 3.04E03
JUP 2023 4307 0.47 3.22E03
APP 230 4225.5 0.05 4.07E03
PTX3 177 99 1.79 5.66E03
PLA2G4A 845.5 542.5 1.56 7.47E03
CTSG 3846.5 891 4.32 7.55E03
IFITM1 208.5 405 0.51 8.51E03
LPAR6 330 649 0.51 8.60E03
CCND2 4057.5 6980 0.58 8.98E03
SEL1L3 2942.5 1823.5 1.61 1.41E02
ITM2A 730.5 2173 0.34 1.45E02
SLC38A1 2730.5 5749.5 0.47 1.70E02
EMP1 478 698 0.68 1.93E02
EGFL7 799 1628 0.49 2.28E02
JAG1 1032 701.5 1.47 2.56E02
CCNA1 866.5 392.5 2.21 2.60E02
ELANE 2815 1644 1.71 3.66E02
TREM1 1238 565.5 2.19 4.07E02
TNFAIP2 5289 3448 1.53 4.25E02
SLC4A1 255 1005.5 0.25 4.29E02
PRKD3 898 1510.5 0.59 4.33E02
LGALS3BP 5023.5 1190 4.22 4.60E02
TARP 1053.5 503 2.09 4.72E02
HBB 3253 11122.5 0.29 4.72E02
(B)
BAALC 105 527 0.2 1.20E14
HOXA5 3320 167.5 19.82 3.79E26
CD34 310 1862 0.17 1.02E13
GYPC 814 2218.5 0.37 7.62E12
HOXB3 395 93 4.25 1.19E25
HOXB5 687 245.5 2.8 1.53E23
HOXB6 952 14.5 65.66 1.06E22
RASGRP3 743 197 3.77 1.93E11
MAN1A1 1025 2469.5 0.42 7.51E11
PBX3 3406 647 5.26 1.58E22
HOXB2 2268 245 9.26 2.71E23
CD200 69 538 0.13 1.63E16
PDGFD 573 205.5 2.79 2.23E18
COL4A5 1161 99 11.73 1.03E17
PROM1 288 1468 0.2 2.68E05
HOXA10 1842 304.5 6.05 8.81E23
DMXL2 3644 1164.5 3.13 1.03E17
MEIS1 1761 352.5 5 4.04E21
SMC4 3502 1565.5 2.24 5.65E20
NPR3 440 1493 0.29 7.34E06
ITM2C 712 2538 0.28 3.27E17
MEST 948 2877 0.33 1.20E12
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showed a significant gene expression change and a fold change
over 2.0 or below 0.5 in each training set (n = 32). Correlation to
survival was used as an additional filter (n = 19), and the pipeline
of gene selection for qPCR measurement is depicted in Fig. 2A.
The best performing genes discriminating NPM1 mutant and
wild-type samples were HOXA5, HOXB5, HOXA10, PBX3, MEIS1,
and ITM2A. Of these, ITM2A was the only downregulated gene
(Fig. 2G). Kaplan-Meier curves show that high expression of these
genes was correlated with poor survival (Fig. 2B–F). In the case of
ITM2A, lower expression was associated with worse outcome
(Fig. 2G). Correlation between mutation status and expression
and expression and survival in the TCGA and GSE1159 datasets
for these genes is provided in Figs. 3 and 4, respectively.
Table 5 (continued)
Gene Mutant median Wild median FC P-value
BAHCC1 2543 1273 2 1.15E08
TSPAN13 252 732 0.34 4.82E11
TMEM176B 651 170 3.83 2.21E03
TMEM176A 831 435.5 1.91 8.10E04
JUP 510 1762.5 0.29 1.40E14
APP 43 335.5 0.13 1.90E14
PTX3 722 286 2.52 3.17E07
PLA2G4A 400 187.5 2.13 3.73E15
CTSG 3909 837 4.67 1.05E08
IFITM1 1295 2301 0.56 1.06E08
LPAR6 220 805 0.27 1.24E11
CCND2 2137 5490.5 0.39 3.31E16
SEL1L3 1650 791 2.09 2.16E09
ITM2A 647 1967 0.33 1.75E11
SLC38A1 831 1893.5 0.44 4.41E10
EMP1 281 906.5 0.31 3.13E09
EGFL7 376 965 0.39 1.51E09
JAG1 888 403 2.2 8.53E08
CCNA1 1514 583.5 2.59 2.04E05
ELANE 2466 5811 0.42 1.27E02
TREM1 1158 597.5 1.94 2.99E07
TNFAIP2 2196 1215.5 1.81 2.72E08
SLC4A1 284 794 0.36 4.45E04
PRKD3 269 558.5 0.48 6.82E08
LGALS3BP 2623 996.5 2.63 2.70E09
TARP 5095 2815.5 1.81 3.96E05
HBB 4514 21338.5 0.21 5.18E05
Table 6
NPM1 mutation associated genes that expression was correlated with OS in the
GSE1159 dataset.
Gene HR P-value q-value
HOXA10 0.48 1.63E05 7.99E04
TARP 0.53 1.31E04 2.22E03
HOXA5 0.51 1.69E04 2.22E03
SEL1L3 0.53 1.81E04 2.22E03
MEIS1 0.49 2.85E04 2.76E03
ITM2A 1.96 3.38E04 2.76E03
PLA2G4A 0.59 1.19E03 8.33E03
ELANE 1.8 1.39E03 8.51E03
MEST 1.77 2.06E03 1.12E02
CD34 0.58 2.48E03 1.22E02
JUP 1.76 3.73E03 1.58E02
GYPC 1.57 3.86E03 1.58E02
LGALS3BP 0.62 4.49E03 1.67E02
SMC4 0.62 4.76E03 1.67E02
MAN1A1 1.54 5.38E03 1.76E02
PBX3 0.65 6.02E03 1.84E02
HOXB5 0.63 7.11E03 2.05E02
CTSG 0.63 8.96E03 2.44E02
TSPAN13 0.65 1.03E02 2.66E02
SLC38A1 0.67 1.26E02 3.09E02
IFITM1 1.49 1.49E02 3.48E02
HOXB2 0.68 1.98E02 4.41E02
RASGRP3 0.71 2.79E02 5.94E02
CCND2 1.38 4.21E02 8.24E02
LPAR6 1.41 4.42E02 8.24E02
HOXB3 0.72 4.45E02 8.24E02
EGFL7 1.46 4.54E02 8.24E02
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The prevalence of NPM1mutation was compared to IDH1, IDH2,
and FLT3 mutation status in the training and validation sets by
Chi-square analysis. In the training set, the correlation to IDH1
and FLT3 was significant (chi-stat = 44.7, P < 0.00001 and chi-
stat = 9.2, P = 0.0024, respectively) while the correlation to IDH2
was not significant. Similarly, in the validation set, the correlation
to IDH1 and FLT3 were significant (chi-stat = 5.03, P = 0.024 andchi-stat = 8.2, P = 0.0041, respectively), and IDH2 was not signifi-
cant. Important to note that only 89 patients had simultaneous
mutation state for each gene in the validation set.
Validation of target genes by qPCR in the Semmelweis set
Mutation data were available for all patients in our clinical sam-
ple cohort. In this group, the NPM1 gene was mutated in 25% of
patients (Fig. 5A). The FLT3, IDH2, and IDH1 genes harbored a
mutation in 25%, 14%, and 5% of patients, respectively. The muta-
tion frequency was independent of the sample origin, including
bone marrow and blood (data not shown).
The Semmelweis set contains 169 AML patients (Fig. 1A);
52.6% of the samples were obtained from bone marrow and
47.4% of the samples were collected from peripheral blood. All
samples have overall survival data with a median follow-up time
of 6.92 months. Similar to the training sets, most patients have
intermediate cytogenetic risk (Fig. 5A). Additional clinico-
pathological characteristics of the samples are displayed in
Fig. 5A–D and Table 2. When analyzing the mutation status of
NPM1 in the Semmelweis set, no significant correlation to overall
survival was observed (P = 0.4).
The most significant genes associated with NPM1 mutations as
observed in the training sets was validated by qPCR. The expres-
sions of HOXA5 (P = 3.06E12, FC = 8.3), HOXA10 (P = 2.44E09,
FC = 3.3), HOXB5 (P = 1.86E13, FC = 37), MEIS1 (P = 9.82E10,
FC = 4.4) and PBX3 (P = 1.03E13, FC = 5.4) genes were signifi-
cantly higher while the expression of the ITM2A (P = 0.004,
FC = 0.4) gene was significantly lower in the NPM1 mutant patient
cohort (Fig. 5E–J). Finally, the survival analysis provided a signifi-
cant association between the expression of the HOXA5, HOXA10,
PBX3, and MEIS1 genes and overall survival in the validation
cohort (Fig. 5E–I).
Correlation between HOX genes and co-factors
Pearson’s rank correlation was computed to examine the rela-
tion of gene expression between HOX, MEIS, and PBX genes. All
the P-values were less than 2.2E16. High correlation was found
between HOXA5 and HOXA10, HOXA5 and MEIS1, HOXA10 and
MEIS1, HOXA10 and PBX3, and MEIS1 and PBX3 genes (Fig. 6A).
In Fig. 6B, the potential interplay between HOX genes and
co-factors (PBX3 and MEIS1) in the cell is displayed.Discussion
Genes showing altered expression with NPM1 somatic muta-
tions and altered survival were identified in AML. Interestingly,
NPM1 mutation status per sewas not correlated to survival neither
in the training nor in the validation set. The final set of
NPM1-assicated genes is established in four independent datasets
(three previously published genomic sets and one clinical sample
set collected at the Semmelweis University). The results demon-
strate that the HOXA5, HOXB5, HOXA10, PBX3, MEIS1, and ITM2A
genes show the highest expression change when comparing NPM1
mutant and wild type cohorts. Of these genes, HOXA5, HOXB5,
HOXA10, PBX3, and MEIS1 were upregulated, and the ITM2A gene
was downregulated in the NPM1 mutant tumors. With the excep-
tion of ITM2A, higher expression was also correlated with poor
prognosis.
Homeobox genes are members of transcription factor families
that are grouped into four main clusters (HOXA-D) on four differ-
ent chromosomes. HOX genes play central roles in embryonic
development, differentiation, and proliferation of hematopoietic
cells [38]. Expression changes of HOX genes are also highly
Fig. 2. A–G. Best genes in the training set. Workflow of selecting differentially expressed genes (A). The best performing genes linked to NPM1 mutations in the training set
(B–G). Hazard rates with 95% confidence intervals are shown.
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[39]. In a genome-wide analysis, several HOXA and HOXB genes
with their co-factors were overexpressed in AML with normal
karyotype [40]. HOX expression in AML is restricted to specific
genes in the HOXA or HOXB loci, and are highly correlated with
recurrent cytogenetic abnormalities [41]. Overexpression of HOX
genes results in the expansion of progenitor cell populations and
simultaneously blockade of the differentiation of these cells [42].
Here, three homeobox (HOX) genes were found – HOXA5, HOXB5,
and HOXA10 – that show significantly higher expression in NPM1mutant tumor samples. A previous study revealed that high
expression of HOXA5 is linked with worse survival in AML [38].
In pediatric AML cases, NPM1 mutations affected the expression
of HOXA4, HOXA6, HOXA7, HOXA9, and HOXB9 genes and the
MEIS1 and PBX3 genes [43]. The mechanism of action for upregu-
lation of HOX genes in NPM1 mutated patients remains uncertain.
NPM1 might directly modify the expression of HOX genes, or
NPM1 mutations might inhibit the differentiation of early
hematopoietic progenitors where HOX expression is upregulated
[44]. The results of present study also provide robust clinical
Fig. 3. Validation of NPM1-associated differentially expressed genes in the GSE1159 (A) and TCGA datasets (B).
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connection between NPM1 and HOX expression in AML. In their
study, Brunetti and coworkers show the key role of mutant
NPM1 and its aberrant cytoplasmic localization in inducing HOX
expression. Nuclear re-localization of the mutated protein
(NPM1c) induced immediate downregulation of HOX genes, fol-
lowed by cell differentiation [45].
Hox transcription factors frequently co-operate with PBX (pre-
B-cell leukemia homeobox) and MEIS (myeloid ecotropic viral inte-
gration site homeobox) family genes [46]. These genes are encoded
by homeodomain-containing transcription cofactors, which have
an essential role in some HOX-dependent developmental programs
[47]. HOX proteins from paralog groups 1 to 10 interact with PBX
proteins, whereas interaction with MEIS proteins is limited to
HOX paralogs 9 to 13 [48].
PBX proteins were identified as fusion proteins from chromo-
some translocations causing pre-B cell leukemia in humans [49].
The interaction between PBX and HOX proteins is essential for
HOX function [50] (see Fig. 6B). Earlier studies presented that the
DNA binding affinity of HOX proteins is higher when PBX proteins
are present [51]. In addition, these co-factors can mediate the DNA
target selection of HOX proteins [52]. PBX proteins also bind to
additional factors, such as histone deacetylases (HDACs) and his-
tone acetyltransferases (HATs) to mobilize these factors to the
HOX complexes [53].MEIS proteins are members of HMP (homothorax, meis and
prep) proteins and are identified as proto-oncogenes coactivated
with HOX genes in leukemia [54]. Previous studies demonstrated
that HMP proteins can form complexes with PBX and HOX proteins
[55] (Fig. 6B). MEIS proteins also counteract HDAC activity [56].
PBX-HOX complexes can bind HDACs and repress transcription;
however, this repression can be blocked by MEIS proteins capable
of initiating transcription [56].
ITM2A (integral membrane protein 2A) is a type II membrane
protein that belongs to the ITM2 family [57]. ITM2A is involved
in myogenic differentiation, mesenchymal stem cell differentia-
tion, and autophagy [58]. A patent describing a monoclonal anti-
body against ITM2A for the potential treatment of AML by
inducing ADCC was recently submitted [59]. Decreased ITM2A
expression in AML was described previously, but its function in
the progression of AML is still unclear [14].
These results support the idea of targeting the HOX transcrip-
tion complex in the targeted therapy of NPM1 mutated AML. In
some solid cancers, including lung [60], breast [61], prostate [62],
melanoma [63], and AML cell lines [64], HXR9 is a potent cell pen-
etrating peptide inhibitor targeting HOX proteins by inhibiting the
interaction with PBX cofactors. Alharbi et al. evaluated the mecha-
nism of HXR9 induced cell death and found that HXR9 promotes
apoptosis and necroptosis and its cytotoxicity can be enhanced
by inhibiting protein kinase C (PKC) in AML cell lines [65].
Fig. 4. The expression of HOXA5 (A), HOXB5 (B), HOXA10 (C), PBX3 (D), MEIS1 (E) and ITM2A (F) genes was significantly correlated with OS in the GSE1159 dataset. HRs with
95% confidence intervals are shown.
Fig. 5. A–J. Validation in an independent clinical set. Clinical characteristics of the Semmelweis set (A–D). RT-qPCR for differentially expressed genes with validated
expression linked to NPM1 mutations and survival in the clinical set (E–J). Hazard rates with 95% confidence intervals are shown.
114 Á. Nagy et al. / Journal of Advanced Research 20 (2019) 105–116Conclusions
In summary, by connecting mutation status with a gene
expression signature we identified HOX genes and their co-
factors significantly upregulated in NPM1 mutant tumors. The
expression of these genes also correlated to survival outcome.The strength of this study is the utilization of several different
training sets for feature selection and validation using an inde-
pendent method. Based on these results, the complex involving
the HOX genes with the PBX3 and MEIS1 co-factors may serve
as an advanced therapeutic target in NPM1 mutated AML
patients.
Fig. 6. Correlation between top target genes. Scatterplot and Pearson rank correlation coefficients of gene expression (P < 2.2E16 for each correlation) (A). HOX genes and
identified cofactors act in concert to influence multiple features of a cancer cell (B).
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